Details

Autor(en) / Beteiligte

• Verschuere, Tina
• Toelen, Jaan
• Maes, Wim
• Poirier, Françoise
• Boon, Louis
• Tousseyn, Thomas
• Mathivet, Thomas
• Gerhardt, Holger
• Mathieu, Veronique
• Kiss, Robert
• Lefranc, Florence
• Van Gool, Stefaan W.
• Vleeschouwer, Steven De

Titel

Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity

Ist Teil von

• International journal of cancer, 2014-02, Vol.134 (4), p.873-884

Ort / Verlag

Hoboken, NJ: Wiley-Blackwell

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Galectin‐1 is a glycan‐binding protein, which is involved in the aggressiveness of glioblastoma (GBM) in part by stimulating angiogenesis. In different cancer models, galectin‐1 has also been demonstrated to play a pivotal role in tumor‐mediated immune evasion especially by modulating cells of the adaptive immune system. It is yet unknown whether the absence or presence of galectin‐1 within the glioma microenvironment also causes qualitative or quantitative differences in innate and/or adaptive antitumor immune responses. All experiments were performed in the orthotopic GL261 mouse high‐grade glioma model. Stable galectin‐1 knockdown was achieved via transduction of parental GL261 tumor cells with a lentiviral vector encoding a galectin‐1‐targeting miRNA. We demonstrated that the absence of tumor‐derived but not of host‐derived galectin‐1 significantly prolonged the survival of glioma‐bearing mice as such and in combination with dendritic cell (DC)‐based immunotherapy. Both flow cytometric and pathological analysis revealed that the silencing of glioma‐derived galectin‐1 significantly decreased the amount of brain‐infiltrating macrophages and myeloid‐derived suppressor cells (MDSC) in tumor‐bearing mice. Additionally, we revealed a pro‐angiogenic role for galectin‐1 within the glioma microenvironment. The data provided in this study reveal a pivotal role for glioma‐derived galectin‐1 in the regulation of myeloid cell accumulation within the glioma microenvironment, the most abundant immune cell population in high‐grade gliomas. Furthermore, the prolonged survival observed in untreated and DC‐vaccinated glioma‐bearing mice upon the silencing of tumor‐derived galectin‐1 strongly suggest that the in vivo targeting of tumor‐derived galectin‐1 might offer a promising and realistic adjuvant treatment modality in patients diagnosed with GBM. What's new? Galectin‐1 is a glycan‐binding protein that plays a major role in the aggressiveness of glioblastomas (GBMs), via a number of different mechanisms. In different types of tumors, galectin‐1 has been demonstrated to contribute to tumor‐mediated immune evasion. Whether glioma‐derived galectin‐1 also contributes to glioma‐mediated immune evasion is unknown, however. In this study, the authors found that glioma‐derived galectin‐1 plays an important role in the regulation of myeloid cell accumulation within the tumor microenvironment. They also found that silencing of galectin‐1 could improve glioma‐bearing mice survival. Intratumoral silencing of galectin‐1 may therefore offer a promising adjuvant treatment modality for patients with high‐grade glioma.